2018
Obsessive-Compulsive Symptomatology in Community Youth: Typical Development or a Red Flag for Psychopathology?
Barzilay R, Patrick A, Calkins ME, Moore TM, Wolf DH, Benton TD, Leckman JF, Gur RC, Gur RE. Obsessive-Compulsive Symptomatology in Community Youth: Typical Development or a Red Flag for Psychopathology? Journal Of The American Academy Of Child & Adolescent Psychiatry 2018, 58: 277-286.e4. PMID: 30738554, DOI: 10.1016/j.jaac.2018.06.038.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderMajor psychiatric conditionsObsessive-compulsive symptomsPsychiatric conditionsAssociation of OCSStructured psychiatric interviewSerious psychopathologyRed flagsSuicide ideationMental health helpDepressive episodePsychiatric evaluationPsychiatric interviewLifetime diagnosisPhiladelphia Neurodevelopmental CohortSymptomsSubstantial associationCommunity youthOCS symptomsFemale participantsHigh rateNeurodevelopmental CohortOCD criteriaPsychosisPhenotypic heterogeneity
2016
N-Acetylcysteine in the Treatment of Pediatric Tourette Syndrome: Randomized, Double-Blind, Placebo-Controlled Add-On Trial
Bloch MH, Panza KE, Yaffa A, Alvarenga PG, Jakubovski E, Mulqueen JM, Landeros-Weisenberger A, Leckman JF. N-Acetylcysteine in the Treatment of Pediatric Tourette Syndrome: Randomized, Double-Blind, Placebo-Controlled Add-On Trial. Journal Of Child And Adolescent Psychopharmacology 2016, 26: 327-334. PMID: 27027204, PMCID: PMC6445198, DOI: 10.1089/cap.2015.0109.Peer-Reviewed Original ResearchConceptsBenefit of NACEfficacy of NACYale Global Tic Severity ScaleAttention-deficit/hyperactivity disorderObsessive-compulsive disorderTourette syndromeN-acetylcysteineObsessive-compulsive spectrum disordersSide effectsRecent placebo-controlled trialPediatric Tourette syndromePlacebo-controlled trialCurrent pharmacological treatmentsTreatment of ticsTotal tic scoreSeverity of ticsSubstantial side effectsTic Severity ScaleYears of ageMinimal side effectsPediatric TSPrimary outcomeSecondary outcomesGlutamatergic systemPharmacological treatment
2014
Successful Treatment of Tourette Syndrome With Electroconvulsive Therapy: A Case Report
Guo JN, Kothari JS, Leckman JF, Ostroff RB. Successful Treatment of Tourette Syndrome With Electroconvulsive Therapy: A Case Report. Biological Psychiatry 2014, 79: e13-e14. PMID: 25481620, DOI: 10.1016/j.biopsych.2014.09.020.Peer-Reviewed Original ResearchNeural plasticity in fathers of human infants
Kim P, Rigo P, Mayes LC, Feldman R, Leckman JF, Swain JE. Neural plasticity in fathers of human infants. Social Neuroscience 2014, 9: 522-535. PMID: 24958358, PMCID: PMC4144350, DOI: 10.1080/17470919.2014.933713.Peer-Reviewed Original ResearchConceptsFathers' brainsNeural plasticityLateral prefrontal cortexCurrent longitudinal studyPosterior cingulate cortexVoxel-based morphometry analysisGray matter volumeNeural basisCognitive developmentNeural regionsNeural changesOrbitofrontal cortexPrefrontal cortexWeeks postpartumHuman fathersParental motivationCingulate cortexHuman infantsMood symptomsBrain regionsLongitudinal studyPostpartum mood symptomsMatter volumeMorphometry analysisHuman mothers
2012
Effects of Ketamine in Treatment-Refractory Obsessive-Compulsive Disorder
Bloch MH, Wasylink S, Landeros-Weisenberger A, Panza KE, Billingslea E, Leckman JF, Krystal JH, Bhagwagar Z, Sanacora G, Pittenger C. Effects of Ketamine in Treatment-Refractory Obsessive-Compulsive Disorder. Biological Psychiatry 2012, 72: 964-970. PMID: 22784486, PMCID: PMC3667652, DOI: 10.1016/j.biopsych.2012.05.028.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderKetamine infusionDepression symptomsLow-dose ketamine infusionTreatment-refractory obsessive-compulsive disorderOCD symptomsPathogenesis of OCDIncomplete symptom reliefTreatment-Refractory ObsessiveOpen-label trialRapid antidepressant effectsAspartate glutamate receptorsEffects of ketaminePotent noncompetitive antagonistGlutamate abnormalitiesAntidepressant effectsAntidepressant responseSymptom reliefKetamine effectsComorbid depressionAcute effectsGlutamate receptorsDepressive symptomsNoncompetitive antagonistInfusion
2009
Perfectionism and sensory phenomena: phenotypic components of obsessive-compulsive disorder
Lee JC, Prado HS, Diniz JB, Borcato S, da Silva CB, Hounie AG, Miguel EC, Leckman JF, do Rosário MC. Perfectionism and sensory phenomena: phenotypic components of obsessive-compulsive disorder. Comprehensive Psychiatry 2009, 50: 431-436. PMID: 19683613, DOI: 10.1016/j.comppsych.2008.11.007.Peer-Reviewed Original Research
2005
Antidepressant‐Induced Manic Conversion: A Developmentally Informed Synthesis of the Literature
Lim CJ, Leckman JF, Young C, Martin A. Antidepressant‐Induced Manic Conversion: A Developmentally Informed Synthesis of the Literature. International Review Of Neurobiology 2005, 65: 25-52. PMID: 16140052, DOI: 10.1016/s0074-7742(04)65002-1.Peer-Reviewed Original ResearchConceptsAddition of antidepressantsResolution of symptomsAntidepressant-induced maniaSerotonin reuptake inhibitorsMood stabilizer therapyLess nursing careMost case reportsRapid cyclingManic conversionSpontaneous maniaAntidepressant medicationReuptake inhibitorsAntidepressant exposureBipolar depressionCase reportManic episodesMood destabilizationSpontaneous episodesDistressing conditionSevere depressionClinical recommendationsManic symptomsNursing careSelective SSRIPatient screening
2004
Age Effects on Antidepressant-Induced Manic Conversion
Martin A, Young C, Leckman JF, Mukonoweshuro C, Rosenheck R, Leslie D. Age Effects on Antidepressant-Induced Manic Conversion. JAMA Pediatrics 2004, 158: 773-780. PMID: 15289250, DOI: 10.1001/archpedi.158.8.773.Peer-Reviewed Original ResearchConceptsManic conversionAntidepressant classesPatient ageTime-dependent Cox proportional hazards modelsSelective serotonin reuptake inhibitorsCox proportional hazards modelNonbipolar mood disorderSerotonin reuptake inhibitorsProportional hazards modelRisk of conversionAdministrative national databaseEffect of agePharmacy claimsReuptake inhibitorsAntidepressant exposureDrug therapyTricyclic antidepressantsPeripubertal childrenAge effectsBipolar illnessMood disordersHigh riskMental health usersAntidepressant categoryHazards model